Literature DB >> 28779974

Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy.

Nicola Fossati1, R Jeffrey Karnes2, Michele Colicchia2, Stephen A Boorjian2, Alberto Bossi3, Thomas Seisen3, Nadia Di Muzio4, Cesare Cozzarini4, Barbara Noris Chiorda4, Claudio Fiorino5, Giorgio Gandaglia6, Paolo Dell'Oglio6, Shahrokh F Shariat7, Gregor Goldner8, Steven Joniau9, Antonino Battaglia9, Karin Haustermans10, Gert De Meerleer10, Valérie Fonteyne11, Piet Ost11, Hendrik Van Poppel9, Thomas Wiegel12, Francesco Montorsi6, Alberto Briganti6.   

Abstract

BACKGROUND: Salvage radiation therapy (SRT) is a recommended treatment option for biochemical recurrence after radical prostatectomy (RP). However, its effectiveness may be limited to specific categories of patients.
OBJECTIVE: We aimed to identify the optimal candidates for early SRT after RP. DESIGN, SETTING, AND PARTICIPANTS: The study included 925 node-negative patients treated with SRT after RP at seven institutions. Patients received SRT for either prostate-specific antigen (PSA) rising, or PSA persistence after RP that was defined as PSA level ≥0.1 ng/ml at 1 mo after surgery. All patients received local radiation to the prostate and seminal vesicle bed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome measured was distant metastasis after SRT. Regression tree analysis was used to develop a risk-stratification tool. Multivariable Cox regression analysis and nonparametric curve fitting methods were used to explore the relationship between PSA level at SRT and the probability of metastasis-free survival at 8 yr. RESULTS AND LIMITATIONS: At a median follow-up of 8.0 yr, 130 patients developed distant metastasis. At multivariable analysis, pre-SRT PSA level was significantly associated with distant metastasis (hazard ratio: 1.06, p<0.0001). However, when patients were stratified into five risk groups using regression tree analysis (area under the curve: 85%), early SRT administration provided better metastasis-free survival in three groups only: (1) low risk: undetectable PSA after RP, Gleason score ≤7, and tumour stage ≥pT3b, (2) intermediate risk: undetectable PSA after RP with Gleason score ≥8, (3) high risk: PSA persistence after RP with Gleason score ≤7.
CONCLUSIONS: We developed an accurate risk stratification tool to facilitate the individualised recommendation for early SRT based on prostate cancer characteristics. Early SRT proved to be beneficial only in selected groups of patients who are more likely to be affected by clinically significant but not yet systemic recurrence at the time of salvage treatment administration. PATIENT
SUMMARY: In patients affected by prostate cancer recurrence after radical prostatectomy, the early administration of salvage radiation therapy is beneficial only for selected subgroups of patients. In this study, these groups of patients were identified.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biochemical tumour markers; Neoplasm recurrence; Prostatic neoplasms; Radiotherapy; Salvage therapy

Year:  2017        PMID: 28779974     DOI: 10.1016/j.eururo.2017.07.026

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

1.  Editorial: early PSA-testing after radical prostatectomy-the truth behind the scenes.

Authors:  Julian Hanske; Florian Roghmann; Joachim Noldus; Marko Brock
Journal:  Transl Androl Urol       Date:  2019-07

2.  Prostate cancer: Stratifying salvage radiotherapy utility.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2017-08-31       Impact factor: 14.432

3.  Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.

Authors:  F Casas; I Valduvieco; G Oses; L Izquierdo; I Archila; M Costa; K S Cortes; T Barreto; F Ferrer
Journal:  Clin Transl Oncol       Date:  2018-08-20       Impact factor: 3.405

4.  Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy.

Authors:  D Milonas; A Laenen; Z Venclovas; L Jarusevicius; G Devos; S Joniau
Journal:  Clin Transl Oncol       Date:  2021-08-28       Impact factor: 3.405

5.  Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison.

Authors:  Ian Alberts; George Prenosil; Christos Sachpekidis; Thilo Weitzel; Kuangyu Shi; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-02       Impact factor: 9.236

6.  Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions.

Authors:  Ian Alberts; Christos Sachpekidis; Eleni Gourni; Silvan Boxler; Tobias Gross; George Thalmann; Kambiz Rahbar; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-18       Impact factor: 9.236

Review 7.  Salvage therapy for prostate cancer after radical prostatectomy.

Authors:  Nicholas G Zaorsky; Jeremie Calais; Stefano Fanti; Derya Tilki; Tanya Dorff; Daniel E Spratt; Amar U Kishan
Journal:  Nat Rev Urol       Date:  2021-08-06       Impact factor: 14.432

8.  The Significance of Prostate Specific Antigen Persistence in Prostate Cancer Risk Groups on Long-Term Oncological Outcomes.

Authors:  Daimantas Milonas; Zilvinas Venclovas; Gustas Sasnauskas; Tomas Ruzgas
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

Review 9.  Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?

Authors:  Fabio Zattoni; Isabel Heidegger; Veeru Kasivisvanathan; Alexander Kretschmer; Giancarlo Marra; Alessandro Magli; Felix Preisser; Derya Tilki; Igor Tsaur; Massimo Valerio; Roderick van den Bergh; Claudia Kesch; Francesco Ceci; Christian Fankhauser; Giorgio Gandaglia
Journal:  Front Surg       Date:  2021-07-09

10.  Balancing the benefits and harms of radiotherapy post-radical prostatectomy.

Authors:  Benjamin W Lamb; Omar Alghazo; Declan G Murphy
Journal:  Transl Androl Urol       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.